Pfizer 1Q profit drops 15 pct due to lower sales (Update)

May 5, 2014 by Linda A. Johnson
The Pfizer logo is displayed on the exterior of a former Pfizer factory, Sunday, May 4, 2014, in the Brooklyn borough of New York. The pharmaceutical giant said, Monday, May 5, 2014, that their first-quarter profit dropped 15 percent due to cheaper generic competition continuing to reduce sales of multiple medicines and the end of some partnerships promoting other companies' medicines. (AP Photo/Mark Lennihan)

Despite sharply lower expenses and taxes, Pfizer Inc.'s first-quarter profit dropped 15 percent, due to cheaper generic competition for multiple medicines and some promotion partnerships with other drugmakers ending.

The world's second-biggest drugmaker missed Wall Street's revenue expectations by $730 million, but narrowly beat profit expectations. Its shares fell almost 3 percent in afternoon trading.

The New York-based company has seen its revenue shrink since 2011 as inexpensive copycat pills hurt sales of about 20 off-patent drugs that once brought in billions annually, particularly cholesterol fighter Lipitor, the top-selling drug of all time with peak revenue of nearly $13 billion.

According to Pfizer, "the vast majority" of generic competition will be over by the end of 2015.

Meanwhile, Pfizer said it's reviewing its options after British rival AstraZeneca PLC on Friday rejected Pfizer's third acquisition proposal, this time for about $106 billion. Pfizer has been trying since January to get AstraZeneca to discuss a deal that would include Pfizer moving its official domicile —but not its corporate offices—to London, a move that would reduce Pfizer's income tax rate.

The maker of Viagra said net income was $2.33 billion, or 36 cents per share, for January through March, down from $2.75 billion, or 38 cents per share, a year earlier.

Excluding one-time charges, income was 57 cents per share, two cents less than analysts expected.

Revenue totaled $11.35 billion, down 9 percent. Analysts expected $12.08 billion.

Among Pfizer's top sellers, sales rose 8 percent to $1.15 billion for pain and fibromyalgia treatment Lyrica and 4 percent to $914 million for immune disorder drug Enbrel. Sales of pneumonia vaccine Prevnar were flat at $927 million, while key newer medicines—rheumatoid arthritis pill Xeljanz and cancer drugs Xalkori and Inlyta—remain disappointing at less than $100 million in the quarter.

"Our new products are just beginning to rev up," Chief Financial Officer Frank D'Amelio said in an interview with The Associated Press. "The business will pick up."

Research head Mikael Dolsten said that over the next nine months, Pfizer could win U.S. regulatory approval for two new drugs—an abuse-resistant opioid painkiller and a vaccine against meningitis B—and could get approvals for new uses for two other drugs. In addition, the Food and Drug Administration should decide by end of June whether Pfizer can apply for approval of its breakthrough drug for advanced breast cancer, palbociclib, based on mid-stage patient testing results. Otherwise, Pfizer will have to do a third, larger round of tests, delaying potential approval for well over a year.

Pfizer confirmed its 2014 adjusted profit forecast for earnings per share of $2.20 to $2.30 and revenue of $49.2 billion to $52.3 billion. Analysts expect earnings of $2.24 per share on revenue of $49.77 billion.

For the first time, Pfizer reported separate operating results for its three business segments, to give investors more insight into performance as the company considers eventually breaking off some of its business.

All three segments reported sales at least slightly below 2013's first quarter. Only the segment that includes vaccines, cancer drugs and consumer health products posted higher income, up 6 percent to $1.06 billion. Pfizer reported income of $1.77 billion for its newer medicines business and $4.05 billion for its older "established" prescription drugs.

Its shares fell 82 cents, or 2.7 percent, to $29.93 in afternoon trading. Its shares have been about so far this year.

Explore further: Pfizer 2Q mixed, maintains 2013 outlook

Related Stories

Pfizer 2Q mixed, maintains 2013 outlook

July 30, 2013

Pfizer's second-quarter net income more than quadrupled, helped by the sale of its animal health business. The world's second-largest drugmaker beat Wall Street's earnings expectations, though revenue continued to decline ...

Pfizer 3Q net falls due to generics, higher costs

October 29, 2013

Pfizer Inc.'s third-quarter profit dropped 19 percent as competition from generic drugs continued to cut sales, while lower operating expenses failed to offset higher taxes and charges.

Pfizer's 4Q net plunges on charges, sales decline

January 28, 2014

Drugmaker Pfizer said Tuesday that fourth-quarter profit plunged 59 percent because of discontinued operations, restructuring and other charges, and generic competition continuing to siphon off revenue from former blockbuster ...

Recommended for you

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.